H.R. 8205 · 119th Congress (2025–2027)
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The act reauthorizes
- grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
- grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
- a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.
Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
Show official title
To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
Enacted
Public law number: P.L. 119-138
This bill’s path
211 days after it was introduced
This is H.R. 8205’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced4 months
Passed House
Passed Senate
Resolving differences
Not neededsame bill text
Sent to President
Signed into law
- Sponsor
- Rep. Mike Quigley (D-IL-5)
- Cosponsors
103 cosponsors
1 original · 102 later
39 R · 64 D
- Rep. Ken Calvert (R-CA-41)· Original · Apr 6, 2026
- Rep. Jake Auchincloss (D-MA-4)· Later · Apr 9, 2026
- Rep. Angie Craig (D-MN-2)· Later · Apr 9, 2026
- Rep. Scott DesJarlais (R-TN-4)· Later · Apr 9, 2026
- Rep. Brian K. Fitzpatrick (R-PA-1)· Later · Apr 9, 2026
- Rep. Michael T. McCaul (R-TX-10)· Later · Apr 9, 2026
- Rep. Janice D. Schakowsky (D-IL-9)· Later · Apr 9, 2026
- Rep. Jason Crow (D-CO-6)· Later · Apr 14, 2026
- Rep. Jeff Hurd (R-CO-3)· Later · Apr 14, 2026
- Rep. Gwen Moore (D-WI-4)· Later · Apr 14, 2026
- Rep. Bradley Scott Schneider (D-IL-10)· Later · Apr 14, 2026
- Rep. Glenn Thompson (R-PA-15)· Later · Apr 14, 2026
- Rep. David G. Valadao (R-CA-22)· Later · Apr 14, 2026
- Rep. Suzanne Bonamici (D-OR-1)· Later · Apr 15, 2026
- Rep. David P. Joyce (R-OH-14)· Later · Apr 15, 2026
- Rep. Maria Elvira Salazar (R-FL-27)· Later · Apr 15, 2026
- Rep. Marc A. Veasey (D-TX-33)· Later · Apr 15, 2026
- Rep. Gus M. Bilirakis (R-FL-12)· Later · Apr 16, 2026
- Rep. Andrew R. Garbarino (R-NY-2)· Later · Apr 16, 2026
- Rep. Stephen F. Lynch (D-MA-8)· Later · Apr 16, 2026
- Rep. Brad Sherman (D-CA-32)· Later · Apr 16, 2026
- Rep. Don Bacon (R-NE-2)· Later · Apr 20, 2026
- Rep. Tom Cole (R-OK-4)· Later · Apr 20, 2026
- Rep. Steve Cohen (D-TN-9)· Later · Apr 20, 2026
- Rep. Madeleine Dean (D-PA-4)· Later · Apr 20, 2026
- Rep. Valerie P. Foushee (D-NC-4)· Later · Apr 20, 2026
- Rep. Jay Obernolte (R-CA-23)· Later · Apr 20, 2026
- Rep. Pete Sessions (R-TX-17)· Later · Apr 20, 2026
- Rep. Adam Smith (D-WA-9)· Later · Apr 20, 2026
- Rep. John H. Rutherford (R-FL-5)· Later · Apr 21, 2026
- Rep. Terri A. Sewell (D-AL-7)· Later · Apr 21, 2026
- Rep. Danny K. Davis (D-IL-7)· Later · Apr 22, 2026
- Rep. Joe Wilson (R-SC-2)· Later · Apr 22, 2026
- Rep. Robert B. Aderholt (R-AL-4)· Later · Apr 23, 2026
- Rep. Ritchie Torres (D-NY-15)· Later · Apr 23, 2026
- Rep. Tracey Mann (R-KS-1)· Later · Apr 30, 2026
- Del. Eleanor Holmes Norton (D-DC)· Later · Apr 30, 2026
- Rep. Raja Krishnamoorthi (D-IL-8)· Later · May 4, 2026
- Rep. Jefferson Van Drew (R-NJ-2)· Later · May 4, 2026
- Rep. Mark Alford (R-MO-4)· Later · May 7, 2026
- Rep. Nick LaLota (R-NY-1)· Later · May 7, 2026
- Rep. Kim Schrier (D-WA-8)· Later · May 7, 2026
- Rep. Lauren Underwood (D-IL-14)· Later · May 7, 2026
- Rep. Debbie Dingell (D-MI-6)· Later · May 11, 2026
- Rep. Chuck Edwards (R-NC-11)· Later · May 11, 2026
- Rep. Young Kim (R-CA-40)· Later · May 11, 2026
- Rep. Doris O. Matsui (D-CA-7)· Later · May 11, 2026
- Rep. Mike Bost (R-IL-12)· Later · May 12, 2026
- Rep. Mike Thompson (D-CA-4)· Later · May 12, 2026
- Rep. Paul Tonko (D-NY-20)· Later · May 12, 2026
- Rep. Rashida Tlaib (D-MI-12)· Later · May 12, 2026
- Rep. Tim Walberg (R-MI-5)· Later · May 12, 2026
- Rep. Randy K. Weber, Sr. (R-TX-14)· Later · May 12, 2026
- Rep. Stephanie I. Bice (R-OK-5)· Later · May 13, 2026
- Rep. Suzan K. DelBene (D-WA-1)· Later · May 13, 2026
- Rep. J. Luis Correa (D-CA-46)· Later · May 14, 2026
- Rep. Mario Diaz-Balart (R-FL-26)· Later · May 14, 2026
- Rep. Timothy M. Kennedy (D-NY-26)· Later · May 14, 2026
- Rep. Darin LaHood (R-IL-16)· Later · May 14, 2026
- Rep. Steve Womack (R-AR-3)· Later · May 15, 2026
- Rep. George Whitesides (D-CA-27)· Later · May 15, 2026
- Rep. Sanford D. Bishop, Jr. (D-GA-2)· Later · May 19, 2026
- Rep. David Rouzer (R-NC-7)· Later · May 19, 2026
- Rep. Robin L. Kelly (D-IL-2)· Later · May 21, 2026
- Rep. Julia Letlow (R-LA-5)· Later · May 21, 2026
- Rep. Mark E. Amodei (R-NV-2)· Later · May 26, 2026
- Rep. Josh Gottheimer (D-NJ-5)· Later · May 26, 2026
- Rep. Tim Moore (R-NC-14)· Later · May 29, 2026
- Rep. John R. Carter (R-TX-31)· Later · Jun 2, 2026
- Rep. Emanuel Cleaver (D-MO-5)· Later · Jun 2, 2026
- Rep. Greg Stanton (D-AZ-4)· Later · Jun 2, 2026
- Rep. Eugene Simon Vindman (D-VA-7)· Later · Jun 10, 2026
- Rep. Robert J. Wittman (R-VA-1)· Later · Jun 10, 2026
- Rep. Janelle S. Bynum (D-OR-5)· Later · Jun 11, 2026
- Rep. Michael Guest (R-MS-3)· Later · Jun 11, 2026
- Rep. Alma S. Adams (D-NC-12)· Later · Jul 9, 2026
- Rep. Joyce Beatty (D-OH-3)· Later · Jul 9, 2026
- Rep. Nikki Budzinski (D-IL-13)· Later · Jul 9, 2026
- Rep. Sean Casten (D-IL-6)· Later · Jul 9, 2026
- Rep. Troy A. Carter (D-LA-2)· Later · Jul 9, 2026
- Rep. Herbert C. Conaway, Jr. (D-NJ-3)· Later · Jul 9, 2026
- Rep. Donald G. Davis (D-NC-1)· Later · Jul 9, 2026
- Rep. Adelita S. Grijalva (D-AZ-7)· Later · Jul 9, 2026
- Rep. James A. Himes (D-CT-4)· Later · Jul 9, 2026
- Rep. Jahana Hayes (D-CT-5)· Later · Jul 9, 2026
- Rep. Jonathan L. Jackson (D-IL-1)· Later · Jul 9, 2026
- Rep. Marcy Kaptur (D-OH-9)· Later · Jul 9, 2026
- Rep. John B. Larson (D-CT-1)· Later · Jul 9, 2026
- Rep. Greg Landsman (D-OH-1)· Later · Jul 9, 2026
- Rep. George Latimer (D-NY-16)· Later · Jul 9, 2026
- Rep. Carol D. Miller (R-WV-1)· Later · Jul 9, 2026
- Rep. Seth Magaziner (D-RI-2)· Later · Jul 9, 2026
- Rep. Sarah McBride (D-DE)· Later · Jul 9, 2026
- Rep. Analilia Mejia (D-NJ-11)· Later · Jul 9, 2026
- Rep. Chellie Pingree (D-ME-1)· Later · Jul 9, 2026
- Rep. Scott H. Peters (D-CA-50)· Later · Jul 9, 2026
- Rep. Deborah K. Ross (D-NC-2)· Later · Jul 9, 2026
- Rep. Josh Riley (D-NY-19)· Later · Jul 9, 2026
- Rep. Thomas R. Suozzi (D-NY-3)· Later · Jul 9, 2026
- Rep. Mary Gay Scanlon (D-PA-5)· Later · Jul 9, 2026
- Rep. Melanie A. Stansbury (D-NM-1)· Later · Jul 9, 2026
- Rep. Eric Sorensen (D-IL-17)· Later · Jul 9, 2026
- Rep. Bonnie Watson Coleman (D-NJ-12)· Later · Jul 9, 2026
- Policy area
- Health
- Subjects
- Department of Health and Human Services
- Drug therapy
- Food and Drug Administration (FDA)
- Government information and archives
- Health programs administration and funding
- Internet, web applications, social media
- Medical research
- National Institutes of Health (NIH)
3 more
- Neurological disorders
- Public-private cooperation
- Research administration and funding
On this page
Spending
The enacted law text (Public Law 119–138) is not available locally.
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
▸ 6 committee actions · Apr 6, 2026 – Jul 9, 2026
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Subcommittee markup session held
Subcommittee Consideration and Mark-up Session Held
Sources
- Congress.gov action
- House committee actions
Forwarded by subcommittee
Forwarded by Subcommittee to Full Committee by Voice Vote.
Sources
- Congress.gov action
- House committee actions
Markup session held
Committee Consideration and Mark-up Session Held
Sources
- Congress.gov action
- House committee actions
Ordered reported
Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
Sources
- Congress.gov action
- House committee actions
Reported by committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
Sources
- Congress.gov action
- House floor actions
Passed House
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
The House passed the bill as amended.
Document: Engrossed in House
Sources
- Congress.gov action
- House floor actions
Passed Senate
Passed Senate without amendment by Voice Vote.
The Senate passed the bill.
Sources
- Congress.gov action
- Senate
Enrolled Bill
Congress published an enrolled text of the bill.
Document: Enrolled Bill
Sources
- Congress.gov text versionsEnrolled Bill
Presented to the President
Presented to President.
Sources
- Congress.gov action
- House floor actions
- Latest
Law
Signed by President
Became Public Law 119–138.
Document: Public Law
Sources
- Congress.gov action
- Library of Congress
Committees
- HouseEnergy and CommerceReferred Apr 6, 2026 · Markup May 21, 2026 · Reported Jul 9, 2026H. Rept. 119-733
May 13, 2026 · Markup
Floor record
i
Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.
Jul 20, 2026 · House · Considered under suspension of the rulesCongressional Record H4652–H4654
Accelerating Access to Critical Therapies for Als Reauthorization Act of 2026
Jul 22, 2026 · House · Considered as unfinished businessCongressional Record H5159
Accelerating Access to Critical Therapies for Als Reauthorization Act of 2026
Sep 28, 2026 · Senate · Passed Senate without amendment by Voice VoteCongressional Record S5120
Accelerating Access to Critical Therapies for Als Reauthorization Act of 2026
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House | ||
| Reported in House | ||
| Engrossed in House | ||
| Placed on Calendar Senate | ||
| Public Law | ||
| Enrolled Bill | — |
Titles (2)
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Display title, Short title · Enrolled Bill, Placed on Calendar Senate, Engrossed in House, Reported in House, Introduced in House
To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
Official title · Engrossed in House, Introduced in House